Teva Pharmaceutical Industries (TEVA) Free Cash Flow (2009 - 2026)
Teva Pharmaceutical Industries' (TEVA) quarterly Free Cash Flow came in at $307.0 million in Q2 2026, up 134.35% YoY from $131.0 million in Q2 2025, and up 247.6% on a QoQ basis from -$208.0 million in Q1 2026.
Teva Pharmaceutical Industries (TEVA) Free Cash Flow (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has 18 years of Free Cash Flow data on file, last reported at $307.0 million in Q2 2026.
- Quarterly Free Cash Flow rose 134.35% year-over-year to $307.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.3 billion (up 51.46% YoY) and the FY2025 annual result came in at $1.1 billion, up 53.27% from the prior year.
- Free Cash Flow rose to $307.0 million in Q2 2026, from -$208.0 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $1.1 billion in Q4 2023 to a low of -$284.0 million in Q1 2023.
- A 5-year average of $215.6 million and a median of $168.0 million in 2023 frame the typical range for Free Cash Flow.
- The widest YoY moves for Free Cash Flow: up 5225.0% in 2023, down 134.2% in 2023.
- Tracing TEVA's Free Cash Flow over 5 years: stood at $831.0 million in 2022, then rose by 28.16% to $1.1 billion in 2023, then plunged by 58.12% to $446.0 million in 2024, then soared by 127.8% to $1.0 billion in 2025, then sank by 69.78% to $307.0 million in 2026.
- The last three Free Cash Flow figures came in at $307.0 million (Q2 2026), -$208.0 million (Q1 2026), and $1.0 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | 307.00 Mn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 538.00 Mn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 1.14 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 205.60 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | 329.00 Mn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 128.60 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 244.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Alkermes | 8.21 Bn | 7.55 Bn | 397.90 Mn | 137.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 307.00 Mn |
| Jun 30, 2026 | 307.00 Mn |
| Mar 31, 2026 | -208.00 Mn |
| Mar 31, 2026 | -208.00 Mn |
| Dec 31, 2025 | 1.02 Bn |
| Dec 31, 2025 | 1.02 Bn |
| Sep 30, 2025 | 233.00 Mn |
| Sep 30, 2025 | 233.00 Mn |
| Jun 30, 2025 | 131.00 Mn |
| Jun 30, 2025 | 131.00 Mn |
| Mar 31, 2025 | -232.00 Mn |
| Mar 31, 2025 | -232.00 Mn |
| Dec 31, 2024 | 446.00 Mn |
| Dec 31, 2024 | 446.00 Mn |
| Sep 30, 2024 | 545.00 Mn |
| Sep 30, 2024 | 545.00 Mn |
| Jun 30, 2024 | 6.00 Mn |
| Jun 30, 2024 | 6.00 Mn |
| Mar 31, 2024 | -248.00 Mn |
| Mar 31, 2024 | -248.00 Mn |